Thomas D. Giles
YOU?
Author Swipe
View article: Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events Open
BACKGROUND It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS In this double-blind, randomized clinical trial wit…
View article: Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events Open
BACKGROUND The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS In a double-blind, ...
View article: Blood pressure is a beautiful (but imperfect) biomarker of hypertension. The quixotic quest that fuels the hypertension guideline industry
Blood pressure is a beautiful (but imperfect) biomarker of hypertension. The quixotic quest that fuels the hypertension guideline industry Open
Hypertension is a disease; blood pressure (BP) is a biomarker. However, the 2 terms have become ineluctably bound. Based on BP measurements, the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline defines nor…
View article: Analysis of decreases in systemic arterial pressure and heart rate in response to the hydrogen sulfide donor sodium sulfide
Analysis of decreases in systemic arterial pressure and heart rate in response to the hydrogen sulfide donor sodium sulfide Open
The actions of hydrogen sulfide (H 2 S) on the heart and vasculature have been extensively reported. However, the mechanisms underlying the effects of H 2 S are unclear in the anesthetized rat. The objective of the present study was to inv…
View article: Rationale for nebivolol/valsartan combination for hypertension
Rationale for nebivolol/valsartan combination for hypertension Open
: To treat hypertension, combining two or more antihypertensive drugs from different classes is often necessary. β-Blockers and renin-angiotensin-aldosterone system inhibitors, when combined, have been deemed 'less effective' based on part…
View article: Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension
Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension Open
Antihypertensive efficacy of single‐pill combinations ( SPC s) consisting of a β 1 ‐selective adrenergic blocker with vasodilatory properties via β 3 ‐agonism (nebivolol) and an angiotensin II receptor blocker (valsartan) was demonstrated …
View article: Nebivolol has a beneficial effect in monocrotaline-induced pulmonary hypertension
Nebivolol has a beneficial effect in monocrotaline-induced pulmonary hypertension Open
Pulmonary hypertension is a rare disorder that, without treatment, is progressive and fatal within 3–4 years. Current treatment involves a diverse group of drugs that target the pulmonary vascular bed. In addition, strategies that increase…
View article: Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus
Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus Open
Aim: To provide a perspective on the effect of Sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular (CV) risk reduction in type 2 diabetes mellitus (DM) patients.Background: Sodium-glucose co-transporter 2 inhibitors have b…
View article: Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension Open
After demonstration of the antihypertensive efficacy of the combination of the beta-blocker nebivolol and the angiotensin receptor blocker valsartan in an 8-week, randomized, placebo-controlled trial (N = 4161), we now report the effects o…
View article: Endothelial Progenitor Cells as a Biomarker for Transitional Phenotypes in Hypertension
Endothelial Progenitor Cells as a Biomarker for Transitional Phenotypes in Hypertension Open
Hypertension is a cardiovascular disease associated with elevated blood pressure (BP). The transition from the normotensive state to the disease state phenotype(s) of hypertension displays various intermediate phenotypes. The term “prehype…